Alpha-Mannosidosis: Quantitative Oligosaccharide Biomarker Analysis in Dried Blood Spots for Diagnosis, Newborn Screening, and Treatment Monitoring
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Alpha-mannosidosis (AM) is a debilitating lysosomal storage disorder (LSD) caused by insufficient activity of alpha-mannosidase, an enzyme responsible for cleavage of alpha-linked mannose residues from N-glycan-type oligosaccharides during their degradation. As a result, specific oligosaccharides accumulate in tissues and are also detectable in body fluids. AM is a progressive multi-organ disease for which hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are therapeutic options, however, treatment results depend considerably on early diagnosis. Therefore, inclusion of AM into newborn screening panels would significantly contribute to improving therapeutic outcome.
Methods
A rapid and fully quantitative method for the specific AM oligosaccharide biomarker Man 2 GlcNAc in dried blood spots (DBS) using ultra-performance liquid chromatography coupled to tandem-mass spectrometry was developed. DBS from 420 controls, 27 AM patients (including five newborn screening samples), and 35 patients with other LSDs were analyzed.
Results
A distinct separation in biomarker concentrations was observed between unaffected individuals and untreated AM patients (0.1 – 0.8 vs 3.2 – 11.3 µmol Man 2 GlcNAc/L, p <0.0001). Furthermore, Man 2 GlcNAc concentrations significantly differed between untreated patients and those on ERT ( n = 17, p <0.0001) or after HSCT ( n = 15, p <0.0001), and between both treatment groups ( p <0.0001). Moreover, we demonstrated that this method is appropriate for monitoring treatment efficacy by analysis of samples from individual patients before and after initiation of therapy. We retrospectively analyzed residual samples of dried blood spots (DBS) from routine newborn screening that had been stored from patients with later-confirmed AM, which resulted in clear separation from the concentrations observed in a newborn screening control cohort (7.7 – 11.3 vs 0.1 – 0.8 µmol Man 2 GlcNAc/L, p =0.0001).
Conclusion
We present a simple and rapid method for quantitative analysis of the specific AM oligosaccharide biomarker Man 2 GlcNAc, which is remarkably stable compared to enzymatic assays. Thus, the method is useful for selective screening in suspected cases as well as for monitoring the response to different forms of treatment. Furthermore, Man 2 GlcNAc has the potential to serve as a useful biomarker for newborn screening offering the prospect of earlier treatment initiation, improved therapeutic outcome and higher quality of life for AM patients.
